Effects of interleukin 2 therapy in patients with common variable immunodeficiency (CVID).

Rump, J A; Jahreis, A; Schlesier, M; Stecher, S; Dräger, R; Struff, W G; Peter, H H

Rump, J A; Jahreis, A; Schlesier, M; Stecher, S; Dräger, R; Struff, W G; Peter, H H.

Affiliation

Rump JA; Dept. of Rheumatology, University of Freiburg, FRG.

Immunodeficiency ; 4(1-4): 37-42, 1993.

Article in En | MEDLINE | ID: mdl-8167730

Subject(s)

Common Variable Immunodeficiency/therapy; Interleukin-2/therapeutic use; Common Variable Immunodeficiency/classification; Common Variable Immunodeficiency/immunology; Double-Blind Method; Humans; Immunoglobulin G/biosynthesis; Immunoglobulin M/biosynthesis; Immunoglobulins, Intravenous/therapeutic use; In Vitro Techniques; Interleukin-2/biosynthesis; Leukocytes, Mononuclear/immunology; Lymphocyte Activation; Muromonab-CD3/pharmacology; Pokeweed Mitogens/pharmacology; Receptors, Interleukin-2/metabolism; Tetanus Toxoid/pharmacology

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Interleukin-2 / Common Variable Immunodeficiency Type of study: Clinical_trials Limits: Humans Language: En Journal: Immunodeficiency Journal subject: ALERGIA E IMUNOLOGIA Year: 1993 Document type: Article Country of publication: Switzerland

Search on Google

Add to My VHL

XML

PubMed Links